A method for producing a fatty acid polyoxyethylene methyl ether in which ethylene oxide is added to a fatty acid methyl ester component comprising, as a main component, a fatty acid methyl ester having a fatty acid residue of 18 to 22 carbon atoms, the addition being conducted in the presence of a composite metal oxide catalyst and at least one alcohol selected from the group consisting of diethylene glycol, ethylene glycol, propylene glycol, ethanol, methanol and isopropyl alcohol.

A method for producing a fatty acid polyoxyethylene methyl ether in which ethylene oxide is added to a fatty acid methyl ester component comprising, as a main component, a fatty acid methyl ester having a fatty acid residue of 18 to 22 carbon atoms, the addition being conducted in the presence of a composite metal oxide catalyst and at least one alcohol selected from the group consisting of diethylene glycol, ethylene glycol, propylene glycol, ethanol, methanol and isopropyl alcohol.

A method for producing a fatty acid polyoxyethylene methyl ether in which ethylene oxide is added to a fatty acid methyl ester component comprising, as a main component, a fatty acid methyl ester having a fatty acid residue of 18 to 22 carbon atoms, the addition being conducted in the presence of a composite metal oxide catalyst and at least one alcohol selected from the group consisting of diethylene glycol, ethylene glycol, propylene glycol, ethanol, methanol and isopropyl alcohol.

The present invention relates to a novel method for producing an intermediate expressed by chemical formula 5 that can be effectively used in synthesis of sphingosine-1-phosphate receptor agonist.

The present invention relates to a novel method for producing an intermediate expressed by chemical formula 5 that can be effectively used in synthesis of sphingosine-1-phosphate receptor agonist.

Disclosed are a novel 1,2-diacylglycerol compound that useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4 and IL-6 or chemokine CXCL8 related to the migration of inflammatory cells, a method for preparing the same, and an immunomodulator containing the same as an active ingredient. The 1,2-diacylglycerol compound is represented by Chemical Formula 2 in the patent specification.

Disclosed are a novel 1,2-diacylglycerol compound that useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4 and IL-6 or chemokine CXCL8 related to the migration of inflammatory cells, a method for preparing the same, and an immunomodulator containing the same as an active ingredient. The 1,2-diacylglycerol compound is represented by Chemical Formula 2 in the patent specification.

A novel method for production of hydroxamic acid derivative using a compound represented by the formula [12] as an intermediate, and intermediate therefor.

##STR00001## wherein R.sup.1 represents a methyl group or the like; R.sup.2 represents a methyl group or the like; and R.sup.5 represents a hydrogen atom or the like.

A novel method for production of hydroxamic acid derivative using a compound represented by the formula [12] as an intermediate, and intermediate therefor.

##STR00001## wherein R.sup.1 represents a methyl group or the like; R.sup.2 represents a methyl group or the like; and R.sup.5 represents a hydrogen atom or the like.

A curable composition containing at least one of a haloalkyl ether (meth)acrylate or a haloalkenyl ether (meth)acrylate and, optionally, one or more different types of co-monomers is cured to provide a polymer having advantageous properties as a result of the incorporation of halogenated functionality derived from the haloalkyl/haloalkenyl ether (meth)acrylate monomer.